Christoffer Søvsø Våben
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christoffer Søvsø Våben has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Kresten Krarup Keller
Department of Rheumatology Aarhus University Hospital Aarhus Denmark
4 shared publications - Andreas Wiggers Nielsen
Department of Rheumatology, Aarhus University Hospital , Aarhus
3 shared publications - Ellen-Margrethe Hauge
Department of Rheumatology Aarhus University Hospital Aarhus Denmark
3 shared publications - Agnete Overgaard Donskov
Department of Rheumatology, Aarhus University Hospital , Aarhus
2 shared publications - Berit Dalsgaard Nielsen
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Rheumatology, Horsens Regional Hospital, Horsens, Denmark
2 shared publications - Line Thorndal Moll
Rheumatology Sector, Medical Diagnostic Centre, Silkeborg Regional Hospital , Silkeborg
2 shared publications
Latest Publications
- 21 March 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (4)
Rheumatologist assessment in established polymyalgia rheumatica
Objectives: Patients with established polymyalgia rheumatica (PMR) are often referred from general practitioners (GPs) to rheumatologists. This single-centre cohort study examined the frequency, indications and diagnostic outcomes of patients with established PMR referred to a rheumatology outpatient clinic after initial diagnosis by GPs or rheumatologists in a hospital outpatient setting. Methods: This single-centre retrospective cohort study included patients with established PMR referred to a department of rheumatology (2018–2024). Data from patient records covered time of referral, PMR diagnosis, discharge, re-referral, and indication for and outcome of rheumatologist assessment of patients with established PMR. Symptoms and clinical findings were also documented. Results: Among 237 patients diagnosed by rheumatologists, 52/204 (26%) of discharged patients were re-referred. They had shorter time from diagnosis to discharge than those not re-referred (median: 41 days vs 230 days, P < 0.01). Referrals of the 98 patients diagnosed by GPs were more often prompted by uncertainty about their primary diagnosis of PMR (51% vs 14%, P < 0.01), and less frequently by relapse (27% vs 50%, P < 0.01) or recurrence (11% vs 31%, P < 0.01) compared with patients diagnosed by rheumatologists. The PMR diagnosis was less frequently maintained in patients diagnosed by GPs compared with patients diagnosed by rheumatologists (62% vs 83%, P < 0.05). Conclusion: Re-referral was common among patients with established PMR, and the risk increased with discharge shortly after PMR diagnosis. The diagnosis was revised in one-third of patients diagnosed by GPs, highlighting diagnostic challenges and supporting referral of individuals suspected of PMR consistent with current recommendations.
- 21 March 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (4)
Rheumatologist assessment in established polymyalgia rheumatica
Objectives: Patients with established polymyalgia rheumatica (PMR) are often referred from general practitioners (GPs) to rheumatologists. This single-centre cohort study examined the frequency, indications and diagnostic outcomes of patients with established PMR referred to a rheumatology outpatient clinic after initial diagnosis by GPs or rheumatologists in a hospital outpatient setting. Methods: This single-centre retrospective cohort study included patients with established PMR referred to a department of rheumatology (2018–2024). Data from patient records covered time of referral, PMR diagnosis, discharge, re-referral, and indication for and outcome of rheumatologist assessment of patients with established PMR. Symptoms and clinical findings were also documented. Results: Among 237 patients diagnosed by rheumatologists, 52/204 (26%) of discharged patients were re-referred. They had shorter time from diagnosis to discharge than those not re-referred (median: 41 days vs 230 days, P < 0.01). Referrals of the 98 patients diagnosed by GPs were more often prompted by uncertainty about their primary diagnosis of PMR (51% vs 14%, P < 0.01), and less frequently by relapse (27% vs 50%, P < 0.01) or recurrence (11% vs 31%, P < 0.01) compared with patients diagnosed by rheumatologists. The PMR diagnosis was less frequently maintained in patients diagnosed by GPs compared with patients diagnosed by rheumatologists (62% vs 83%, P < 0.05). Conclusion: Re-referral was common among patients with established PMR, and the risk increased with discharge shortly after PMR diagnosis. The diagnosis was revised in one-third of patients diagnosed by GPs, highlighting diagnostic challenges and supporting referral of individuals suspected of PMR consistent with current recommendations.
- 25 March 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (8) , 4756-4760
The effect of prednisolone initiation and short-term discontinuation on the clinical assessment of polymyalgia rheumatica
Objectives: Approximately half of individuals with suspected PMR initiate prednisolone before rheumatological evaluation, but it is unknown if prednisolone reduces the ability to diagnose PMR. This study evaluated the clinical assessment of a PMR diagnosis before and after prednisolone initiation and after short-term prednisolone discontinuation. Methods: Data from a prospective cohort of treatment-naïve patients with PMR (n = 66) and non-PMR (n = 27) were used to create case report forms (CRFs). All patients were assessed at baseline and patients with PMR were reassessed after 8 weeks of prednisolone treatment (n = 57) and after short-term prednisolone discontinuation at week 10 (n = 48). In total, 198 CRFs were created containing patient demographics, current symptoms, physical examination and blood test results. Six rheumatologists, blinded to diagnosis, prednisolone treatment and visit timing, assessed each CRF, rating the probability of a PMR diagnosis from 0 to 10 and classifying them as PMR or non-PMR. Results: At baseline, CRF assessors effectively distinguished PMR from non-PMR, demonstrating median probabilities of PMR of 7.8 and 2.8, respectively, and a sensitivity/specificity of 85.9%/82.7% for the PMR diagnosis. After prednisolone initiation, the median probability of PMR was 1.0 and sensitivity was 3.5%, followed by a median probability of PMR of 2.3 and a sensitivity of 25% after short-term prednisolone discontinuation. Conclusion: This study shows that clinically assessing PMR becomes challenging after prednisolone initiation, and that short-term prednisolone discontinuation does not improve clinical assessment to pre-treatment levels. Consequently, the study supports recommendations of deferring prednisolone initiation until after specialist evaluation in individuals suspected of having PMR.
- 25 March 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (8) , 4756-4760
The effect of prednisolone initiation and short-term discontinuation on the clinical assessment of polymyalgia rheumatica
Objectives: Approximately half of individuals with suspected PMR initiate prednisolone before rheumatological evaluation, but it is unknown if prednisolone reduces the ability to diagnose PMR. This study evaluated the clinical assessment of a PMR diagnosis before and after prednisolone initiation and after short-term prednisolone discontinuation. Methods: Data from a prospective cohort of treatment-naïve patients with PMR (n = 66) and non-PMR (n = 27) were used to create case report forms (CRFs). All patients were assessed at baseline and patients with PMR were reassessed after 8 weeks of prednisolone treatment (n = 57) and after short-term prednisolone discontinuation at week 10 (n = 48). In total, 198 CRFs were created containing patient demographics, current symptoms, physical examination and blood test results. Six rheumatologists, blinded to diagnosis, prednisolone treatment and visit timing, assessed each CRF, rating the probability of a PMR diagnosis from 0 to 10 and classifying them as PMR or non-PMR. Results: At baseline, CRF assessors effectively distinguished PMR from non-PMR, demonstrating median probabilities of PMR of 7.8 and 2.8, respectively, and a sensitivity/specificity of 85.9%/82.7% for the PMR diagnosis. After prednisolone initiation, the median probability of PMR was 1.0 and sensitivity was 3.5%, followed by a median probability of PMR of 2.3 and a sensitivity of 25% after short-term prednisolone discontinuation. Conclusion: This study shows that clinically assessing PMR becomes challenging after prednisolone initiation, and that short-term prednisolone discontinuation does not improve clinical assessment to pre-treatment levels. Consequently, the study supports recommendations of deferring prednisolone initiation until after specialist evaluation in individuals suspected of having PMR.
- 19 November 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (5) , 3210-3211
Comment on: ‘Real-world outcomes of a dedicated fast-track polymyalgia rheumatica clinic’
- 19 November 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (5) , 3210-3211
Comment on: ‘Real-world outcomes of a dedicated fast-track polymyalgia rheumatica clinic’
- 1 October 2021
- Published by Elsevier in Joint Bone Spine
- Vol. 88 (5) , 105185
Fast track clinic for early diagnosis of polymyalgia rheumatica: Impact on symptom duration and prednisolone initiation
- 1 October 2021
- Published by Elsevier in Joint Bone Spine
- Vol. 88 (5) , 105185
Fast track clinic for early diagnosis of polymyalgia rheumatica: Impact on symptom duration and prednisolone initiation